Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate, quantity: 393.36 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; purified talc; hyprolose; hypromellose; magnesium stearate; propylene glycol; purified water; isopropyl alcohol; iron oxide black; titanium dioxide; macrogol 400; indigo carmine aluminium lake - for the treatment of the following infections caused by susceptible organisms, in adults and children 12 years and older: lower respiratory infections, including community acquired pneumonia of mild to moderate severity (excluding atypical pneumonia), acute bronchitis and exacerbation of chronic bronchitis. upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis. symptomatic lower urinary tract infections, including cystitis. skin and skin structure infections.

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - cefaclor monohydrate -

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets usp and other antibacterial drugs, cefaclor extended-release tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. the safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have not been established. when administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the desig

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 500 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes   lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae , haemophilus influenzae, and streptococcus pyogenes   pharyngitis and tonsillitis , caused by streptococcus pyogenes   note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphy

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - cefaclor monohydrate -

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle medical - cefaclor - capsules hard - 250 milligram - cefaclor

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle medical - cefaclor - capsules hard - 500 milligram - cefaclor

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae, haemophilus influenzae , and streptococcus. note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cef

United States - English - NLM (National Library of Medicine)

rebel distributors corp - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg in 5 ml - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae, haemophilus influenzae , and streptococcus. note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is gene

Ireland - English - HPRA (Health Products Regulatory Authority)

strides shasun (uk) ltd - cefaclor monohydrate - capsules hard - 500 milligram - second-generation cephalosporins